Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Not Confirmed
Not Confirmed
04-06 September, 2025
Not Confirmed
Not Confirmed
08-11 September, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Industry Trade Show
Not Confirmed
04-06 September, 2025
Industry Trade Show
Not Confirmed
08-11 September, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-approvals-drop-24-in-h1-2025-gsk-s-uti-med-vertex-s-non-opioid-painkiller-lead-pack-of-first-in-class-meds
25 Aug 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/08/25/3138346/0/en/Incyclix-Bio-Secures-11-25-Million-Series-B-Extension-to-Advance-the-Phase-1-2-Clinical-Trial-of-INX-315-in-Patients-with-CDK4-6-Inhibitor-Resistant-ER-HER2-Breast-Cancer-or-CCNE1-.html
29 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/29/3070088/0/en/Incyclix-Bio-Granted-U-S-FDA-Fast-Track-Designation-for-INX-315-to-Treat-CCNE1-Amplified-Platinum-Resistant-Refractory-Ovarian-Cancer.html
13 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/13/3025828/0/en/Incyclix-Bio-Announces-Publication-in-Nature-Communications-Highlighting-Biomarkers-of-Response-to-CDK2-Inhibition.html
13 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/13/2996733/0/en/Incyclix-Bio-Announces-Interim-Clinical-Data-from-the-Phase-1-2-Clinical-Trial-of-INX-315-in-Patients-with-CDK4-6-Inhibitor-Resistant-ER-HER2-Breast-Cancer-or-CCNE1-Amplified-Solid.html
18 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/18/2982655/0/en/Incyclix-Bio-Announces-Clinical-Trial-Collaboration-and-Supply-Agreement-with-Lilly-to-Evaluate-INX-315-in-Combination-with-Verzenio-abemaciclib-and-Fulvestrant-in-HR-HER2-Breast-C.html
12 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/12/2978967/0/en/Incyclix-Bio-Expands-Board-of-Directors-with-Appointment-of-Norman-E-Sharpless-MD.html
ABOUT THIS PAGE